Overall survival at 2 years was 57% (41–70). The authors showed that venetoclax plus decitabine is a less toxic alternative to traditional intensive chemotherapy, thus allowing a higher proportion of ...

Sangeetha Venugopal, MD, MS, discussed the evolving landscape of acute myeloid leukemia treatment as well as unmet needs ...

The following is a summary of “Impact of critical illness on continuation of anticancer treatment and prognosis of patients with aggressive hematological malignancies,” published in the September 2024 ...

4 Her findings suggested that structural racism directly impacts survival outcomes in AML. 5 After adjusting for neighborhood ...

The researchers suggest certain refinements to the 2022 European LeukemiaNet classification model for patients aged 60 years ...

The UK Medicines and Healthcare products Regulatory Agency previously confirmed the asset’s safety and efficacy.

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced ...

ICT01 showed tolerable safety and promising clinical activity as a monotherapy and is now being investigated in combination ...

Today’s positive decision follows the manufacturer, Daiichi Sankyo, offering a fair price for the treatment that the National Institute for Health and Care Excellence (NICE) determined to be ...

More than 750 advocates with the American Cancer Society took to Capitol Hill to lobby for change. They are demanding ...